Market Report on Blood Product Industry in China 2018-2022

1
Market Report on Blood Product Industry in China
2018-2022
www.marketreportsonchina.com
2
Summary
As a category of biological products, a Blood
Product is a kind of biological active
preparation manufactured based on health human
blood plasma with biological techniques or plasma
separation and purification technologies.
According to patients of different diseases,
different contents of plasma protein are
separated and manufactured into specific blood
products. Blood products can be categorized into
human serum albumin, human immunoglobulin and
coagulation factors that have a widest variety of
products. 
www.marketreportsonchina.com
3
(No Transcript)
4
The concentration rate of global blood product
industry is rather high. The four enterprises of
developed countries, CSL Behring, Baxter, Grifols
and Octapharma, occupy over 80 of global market
shares. Currently, the global blood industry
maintains relatively stable, with emerging
markets serving as major driving
forces. According to China will become one of
the major global blood product markets as its
economy develops. Chinese government imposes
strict regulations on production, sales and
import of blood products. In addition, the
government implements a lot release system of
biological products (including blood products and
vaccines), compulsorily inspecting and verifying
every batch of such products when leaving factory
or being imported.
www.marketreportsonchina.com
5
According to market research by about 30 blood
product manufacturers have been authenticated by
the Chinese government by the end of 2017. But
indeed, only 20 of them operate under normal
production. Since 2012, mergers and acquisitions
have emerged in China's blood product industry.
Examples include Jiangxi Boya Bio-Pharmaceutical
Co., Ltd. purchasing partial stake of Zhejiang
Haikang Biological Products Co., Ltd., Beijing
Tiantan Biological Products Co., Ltd. acquiring
Chengdu Rosen Pharmaceutical Co., Ltd. and
Humanwell Healthcare Group Co., Ltd. acquiring
Wuhan Rui De Biological Products Co., Ltd. 
www.marketreportsonchina.com
6
In 2001, the Chinese government announced that
new blood product manufacturers would be no
longer authenticated for the safety of blood and
blood products. If overseas blood product
manufacturers desire to enter Chinese market,
they can either export their products directly to
China or acquire existing blood product
manufacturers in China. For example, in August
2017, CSL Behring spent USD 352 million on
purchasing 80 stake of Wuhan Zhongyuan Rui De
Biological Products Co., Ltd., a subsidiary of
Humanwell Healthcare Group Co., Ltd. On the third
of August, 2017, CSL officially announced that it
had completed the deal with Humanwell and had
taken over business operations of Rui De. CSL
Behring temporarily launched only albumin on
Chinese market.
www.marketreportsonchina.com
7
Table of Contents
I Basic Concept of Blood Products 1.1 Definition
of Blood Products 1.2 Classification of Blood
Products 1.2.1 Albumin 1.2.2 Immune
Globulin 1.2.3 Coagulation Factors 1.2.4 Other
Categories   II Overview of Global Blood Product
Industry, 2013-2017 2.1 Industry Overview 2.1.1
Development Process 2.1.2 Market
Competition 2.1.3 Supply Status 2.1.4 Demand
Status
www.marketreportsonchina.com
8
Full Report
Market Report on Blood Product Industry in China
2018-2022
Contact Us Phone No 91 22 27810773 Email
info_at_marketreportsonchina.com Website
http//www.marketreportsonchina.com Twitter
https//twitter.com/ReportsonChina Facebook
https//www.facebook.com/chinamarketreport LinkedI
n https//www.linkedin.com/company/3694978